Cargando…

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy

INTRODUCTION: CD105 is an angiogenic biomarker that is useful to determine the microvessel density (MVD) within a tumor, namely, in highly vascularized tumors like glioblastoma (GBM). However, its expression has shown inconsistent associations with the prognosis of GBM patients. The aim of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bastos, António G. P., Carvalho, Bruno, Silva, Roberto, Leitão, Dina, Linhares, Paulo, Vaz, Rui, Lima, Jorge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486379/ https://www.ncbi.nlm.nih.gov/pubmed/36147918 http://dx.doi.org/10.3389/fonc.2022.910196

Ejemplares similares

Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy
por: Kasprzak, Aldona, et al.
Publicado: (2018)

Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer
por: Nogués, Ana, et al.
Publicado: (2020)

Expression of endoglin (CD105) in cervical cancer
por: Zijlmans, H J, et al.
Publicado: (2009)

PROGNOSTIC ROLE OF CD44 EXPRESSION AND NEOVASCULARIZATION DETERMINED BY ENDOGLIN (CD105) IN GLIOBLASTOMA PATIENTS
por: Mihić, Josip, et al.
Publicado: (2019)

Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma
por: Di Paolo, Virginia, et al.
Publicado: (2018)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

Study of expression of endoglin (CD105) in oral squamous cell carcinoma
por: Mahapatra, Niva, et al.
Publicado: (2021)

Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma
por: Yu, Decai, et al.
Publicado: (2007)

Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
por: Bock, Annika J., et al.
Publicado: (2011)

ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours
por: Gromova, Petra, et al.
Publicado: (2012)

Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis
por: Ollauri-Ibáñez, Claudia, et al.
Publicado: (2020)

Hot and Cold Tumors: Is Endoglin (CD105) a Potential Target for Vessel Normalization?
por: Ollauri-Ibáñez, Claudia, et al.
Publicado: (2021)

Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review
por: Sier, Vincent Q., et al.
Publicado: (2021)

Horoscopic role of CD105 (Endoglin) in progression of oral lichen planus: An immunohistochemical study
por: Parvathala, Poornima, et al.
Publicado: (2021)

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
por: Carvalho, Bruno, et al.
Publicado: (2021)

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
por: Fonsatti, Ester, et al.
Publicado: (2004)

Endoglin (CD105) as a putative prognostic biomarker for colorectal cancer: a systematic review
por: Sur, Daniel, et al.
Publicado: (2022)

Microglial Phenotyping in Neurodegenerative Disease Brains: Identification of Reactive Microglia with an Antibody to Variant of CD105/Endoglin
por: Walker, Douglas G., et al.
Publicado: (2019)

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
por: Ahluwalia, Manmeet S., et al.
Publicado: (2023)

Endoglin (CD105) is a more appropriate marker than CD31 for detecting microvessels in carotid artery plaques
por: Fukumitsu, Ryu, et al.
Publicado: (2013)

Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?
por: Linhares, Paulo, et al.
Publicado: (2020)

Endoglin and TGF-β signaling in glioblastoma
por: Burghardt, Isabel, et al.
Publicado: (2021)

CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma
por: Smith, Stuart J., et al.
Publicado: (2012)

Endoglin (CD105) expression differentiates between aseptic loosening and periprosthetic joint infection after total joint arthroplasty
por: Jansen, Philipp, et al.
Publicado: (2014)

A bioinformatic analysis of the inhibin-betaglycan-endoglin/CD105 network reveals prognostic value in multiple solid tumors
por: Listik, Eduardo, et al.
Publicado: (2021)

Glioblastoma in the elderly: Therapeutic dilemmas
por: Pereira, André F., et al.
Publicado: (2015)

Anti-Human Endoglin (hCD105) Immunotoxin—Containing Recombinant Single Chain Ribosome-Inactivating Protein Musarmin 1
por: Barriuso, Begoña, et al.
Publicado: (2016)

CD105 (Endoglin)-Negative Murine Mesenchymal Stromal Cells Define a New Multipotent Subpopulation with Distinct Differentiation and Immunomodulatory Capacities
por: Anderson, Per, et al.
Publicado: (2013)

Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation
por: Linhares, Paulo, et al.
Publicado: (2013)

The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer
por: Beresford, M J, et al.
Publicado: (2006)

Soluble Endoglin Stimulates Inflammatory and Angiogenic Responses in Microglia That Are Associated with Endothelial Dysfunction
por: Park, Eun S., et al.
Publicado: (2022)

Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma.
por: Altomonte, M., et al.
Publicado: (1996)

5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin
por: Lund, Kaja, et al.
Publicado: (2017)

Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma
por: Hu, Junhui, et al.
Publicado: (2019)

Revisiting anti-angiogenic therapy for recurrent glioblastoma
por: Peters, Katherine B.
Publicado: (2019)

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
por: Liu, Yingmiao, et al.
Publicado: (2014)

Endoglin and Other Angiogenesis Markers in Recurrent Varicose Veins
por: Sánchez, Francisco S. Lozano, et al.
Publicado: (2022)

Immunohistochemical expression of hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP-2 and -9 in endometrial polyps and endometrial cancer type I
por: Peres, Gustavo Filipov, et al.
Publicado: (2018)

Author Index for Volume105
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kr5pnfo03hjnsd6ob1p34se9vj